Erratum: Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity (Journal of Medicinal Chemistry (2015) 58 (2180-2194) DOI:10.1021/jm501258m);Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity

Journal of Medicinal Chemistry

Volumn 58, Issue 5, 2015, Pages 2180-2194

  Bruncko, Milan ^a   Wang, Le ^a   Sheppard, George S ^a   Phillips, Darren C ^a   Tahir, Stephen K ^a   Xue, John ^a   Erickson, Scott ^a   Fidanze, Steve ^a   Fry, Elizabeth ^a   Hasvold, Lisa ^a   Jenkins, Gary J ^a   Jin, Sha ^a   Judge, Russell A ^a   Kovar, Peter J ^a   Madar, David ^a   Nimmer, Paul ^a   Park, Chang ^a   Petros, Andrew M ^a   Rosenberg, Saul H ^a   Smith, Morey L ^a   Song, Xiaohong ^a   Sun, Chaohong ^a   Tao, Zhi Fu ^a   Wang, Xilu ^a   Xiao, Yu ^a   Zhang, Haichao ^a   Tse, Chris ^a   Leverson, Joel D ^a   Elmore, Steven W ^a   Souers, Andrew J ^a   more..

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHOL; 2 INDOLECARBOXYLIC ACID; CASPASE; CHLORIDE; PROTEIN BCL 2; PROTEIN MCL 1; ANTINEOPLASTIC AGENT; MCL1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; MITSUNOBU REACTION; MULTIPLE CANCER; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR CELL LINE; APOPTOSIS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; FACTUAL DATABASE; HUMAN; METABOLISM; MOLECULAR DOCKING; MULTIPLE MYELOMA; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PANCREATIC NEOPLASMS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84924674523     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00616     Document Type: Erratum

References (41)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100, 57-70
2. Adams, J. M.; Cory, S. The BCL-2 apoptotic switch in cancer development and therapy Oncogene 2007, 26, 1324-1337
3. Phillips, D. C.; Dias, H. K. I.; Kitas, G. D.; Griffiths, H. R. Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention Antioxid. Redox Signaling 2010, 12, 743-785
4. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59
5. Rinkenberger, J. L.; Horning, S.; Klocke, B.; Roth, K.; Korsmeyer, S. J. MCL-1 deficiency results in peri-implantation embryonic lethality Genes Dev. 2000, 14, 23-27
6. Opferman, J. T.; Iwasaki, H.; Ong, C. C.; Suh, H.; Mizuno, S.; Akashi, K.; Korsmeyer, S. J. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells Science 2005, 307, 1101-1104
7. Dzhagalov, I.; Dunkle, A.; He, Y. W. The anti-apoptotic BCL-2 family member MCL-1 promotes T lymphocyte survival at multiple stages J. Immunol. 2008, 181, 521-528
8. Steimer, D. A.; Boyd, K.; Takeuchi, O.; Fisher, J. K.; Zambetti, G. P.; Opferman, J. T. Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function Blood 2009, 113, 2805-2815
9. Beroukhim, R.; Mermel, C. H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J. S.; Dobson, J.; Urashima, M.; Mc Henry, K. T.; Pinchback, R. M.; Ligon, A. H.; Cho, Y. J.; Haery, L.; Greulich, H.; Reich, M.; Winckler, W.; Lawrence, M. S.; Weir, B. A.; Tanaka, K. E.; Chiang, D. Y.; Bass, A. J.; Loo, A.; Hoffman, C.; Prensner, J.; Liefeld, T.; Gao, Q.; Yecies, D.; Signoretti, S.; Maher, E.; Kaye, F. J.; Sasaki, H.; Tepper, J. E.; Fletcher, J. A.; Tabernero, J.; Baselga, J.; Tsao, M. S.; Demichelis, F.; Rubin, M. A.; Janne, P. A.; Daly, M. J.; Nucera, C.; Levine, R. L.; Ebert, B. L.; Gabriel, S.; Rustgi, A. K.; Antonescu, C. R.; Ladanyi, M.; Letai, A.; Garraway, L. A.; Loda, M.; Beer, D. G.; True, L. D.; Okamoto, A.; Pomeroy, S. L.; Singer, S.; Golub, T. R.; Lander, E. S.; Getz, G.; Sellers, W. R.; Meyerson, M. The landscape of somatic copy-number alteration across human cancers Nature 2010, 463, 899-905
10. Zhou, P.; Levy, N. B.; Xie, H.; Qian, L.; Lee, C. Y.; Gascoyne, R. D.; Craig, R. W. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes Blood 2001, 97, 3902-3909
11. Glaser, S. P.; Lee, E. F.; Trounson, E.; Bouillet, P.; Wei, A.; Fairlie, W. D.; Izon, D. J.; Zuber, J.; Rappaport, A. R.; Herold, M. J.; Alexander, W. S.; Lowe, S. W.; Robb, L.; Strasser, A. Anti-apoptotic MCL-1 is essential for the development and sustained growth of acute myeloid leukemia Genes Dev. 2012, 26, 120-125
12. Wertz, I. E.; Kusam, S.; Lam, C.; Okamoto, T.; Sandoval, W.; Anderson, D. J.; Helgason, E.; Ernst, J. A.; Eby, M.; Liu, J.; Belmont, L. D.; Kaminker, J. S.; O'Rourke, K. M.; Pujara, K.; Kohli, P. B.; Johnson, A. R.; Chiu, M. L.; Lill, J. R.; Jackson, P. K.; Fairbrother, W. J.; Seshagiri, S.; Ludlam, M. J.; Leong, K. G.; Dueber, E. C.; Maecker, H.; Huang, D. C.; Dixit, V. M. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 Nature 2011, 471, 110-114
13. Wei, S. H.; Dong, K.; Lin, F.; Wang, X.; Li, B.; Shen, J. J.; Zhang, Q.; Wang, R.; Zhang, H. Z. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting MCL-1 gene in pancreatic carcinoma cell Cancer Chemother. Pharmacol. 2008, 62, 1055-1064
14. Kim, S. H.; Ricci, M. S.; El-Deiry, W. S. MCL-1: a gateway to TRAIL sensitization Cancer Res. 2008, 68, 2062-2064
15. Tahir, S. K.; Yang, X.; Anderson, M. G.; Morgan-Lappe, S. E.; Sarthy, A. V.; Chen, J.; Warner, R. B.; Ng, S. C.; Fesik, S. W.; Elmore, S. W.; Rosenberg, S. H.; Tse, C. Influence of BCL-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737 Cancer Res. 2007, 67, 1176-1183
16. Zhang, H.; Guttikonda, S.; Roberts, L.; Uziel, T.; Semizarov, D.; Elmore, S. W.; Leverson, J. D.; Lam, L.-T. MCL-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines Oncogene 2011, 30, 1963-1968
17. Park, C.-M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins J. Med. Chem. 2008, 51, 6902-6915
18. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. ABT-263: a potent and orally bioavailable BCL-2 family inhibitor Cancer Res. 2008, 68, 3421-3428
19. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C. M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. ABT-199, A potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat. Med. 2013, 19, 202-208
20. Tao, Z.-F.; Hasvold, L.; Wang, L.; Wang, X.; Petros, A. M.; Park, C. H.; Boghaert, E. R.; Catron, N. D.; Chen, J.; Colman, P. M.; Czabotar, P. E.; Deshayes, K.; Fairbrother, W. J.; Flygare, J. A.; Hymowitz, S. G.; Jin, S.; Judge, R. A.; Koehler, M. F. T.; Kovar, P. J.; Lessene, G.; Mitten, M. J.; Ndubaku, C. O.; Nimmer, P.; Purkey, H. E.; Oleksijew, A.; Phillips, D. C.; Sleebs, B. E.; Smith, B. J.; Smith, M. L.; Tahir, S. K.; Watson, K. G.; Xiao, Y.; Xue, J.; Zhang, H.; Zobel, K.; Rosenberg, S. H.; Tse, C.; Leverson, J. D.; Elmore, S. W.; Souers, A. J. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity ACS Med. Chem. Lett. 2014, 5, 1088-1093
21. Belmar, J.; Fesik, S. W. Small molecule MCL-1 inhibitors for the treatment of cancer Pharmacol. Ther. 2015, 145, 76-86
22. Varadarajan, S.; Butterworth, M.; Wei, J.; Pellecchia, M.; Dinsdale, D.; Cohen, G. M. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis Neoplasia 2013, 15, 568-578
23. Friberg, A.; Vigil, D.; Zhao, B.; Daniels, R. N.; Burke, J. P.; Garcia-Barrantes, P. M.; Camper, D.; Chauder, B. A.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of potent myeloid cell leukemia 1 (MCL-1) inhibitors using fragment-based methods and structure-based design J. Med. Chem. 2013, 56, 15-30
24. Kim, Y. B.; Balasis, M. E.; Doi, K.; Berndt, N.; DuBoulay, C.; Hu, C. C.; Guida, W.; Wang, H. G.; Sebti, S. M.; Del Valle, J. R. Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the MCL-1/BIMBH3 interaction Bioorg. Med. Chem. Lett. 2012, 22, 5961-5965
25. Richard, D. J.; Lena, R.; Bannister, T.; Blake, N.; Pierceall, W. E.; Carlson, N. E.; Keller, C. E.; Koenig, M.; He, Y.; Minond, D.; Mishra, J.; Cameron, M.; Spicer, T.; Hodder, P.; Cardone, M. H. Hydroxyquinoline-derived compounds and analoguing of selective MCL-1 inhibitors using a functional biomarker Bioorg. Med. Chem. 2013, 21, 6642-6649
26. Abulwerdi, F.; Liao, C.; Liu, M.; Azmi, A. S.; Aboukameel, A.; Mady, A. S.; Gulappa, T.; Cierpicki, T.; Owens, S.; Zhang, T.; Sun, D.; Stuckey, J. A.; Mohammad, R. M.; Nikolovska-Coleska, Z. A novel small-molecule inhibitor of MCL-1 blocks pancreatic cancer growth in vitro and in vivo Mol. Cancer Ther. 2014, 13, 565-575
27. Abulwerdi, F. A.; Liao, C.; Mady, A.; Gavin, J.; Shen, C.; Cierpicki, T.; Stuckey, J. A.; Showalter, H. D. H.; Nikolovska-Coleska, Z. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective MCL-1 inhibitors: structure-based design, synthesis, SAR and biological evaluation J. Med. Chem. 2014, 57, 4111-4133
28. Doi, K.; Li, R.; Sung, S.-S.; Wu, H.; Liu, Y.; Manieri, W.; Krishnegowda, G.; Awaad, A.; Dewey, A.; Liu, X.; Amin, S.; Cheng, C.; Qin, Y.; Schonbrunn, E.; Daughdrill, G.; Loughran, T. P., Jr.; Sebti, S.; Wang, H.-G. Discovery of marinopyrrole A (maritoclax) as a selective MCL-1 antagonist that overcomes ABT-737 resistance by binding to and targeting MCL-1 for proteasomal degradation J. Biol. Chem. 2012, 287, 10224-10235
29. Varadarajan, S.; Vogler, M.; Butterworth, M.; Dinsdale, D.; Walensky, L. D.; Cohen, G. M. Evaluation and critical assessment of putative MCL-1 inhibitors Cell Death Differ. 2013, 20, 1475-1484
30. Eichhorn, J. M.; Alford, S. E.; Hughes, C. C.; Fenical, W.; Chambers, T. C. Purported MCL-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for MCL-1-dependent cell lines Cell Death Dis. 2013, 4, e880-e881
31. Elmore, S. W.; Souers, A. J.; Bruncko, M.; Song, X.; Wang, X.; Hasvold, L. A.; Wang, L.; Kunzer, A. R.; Park, C.-M.; Wendt, M. D.; Tao, Z.-F. 7-Substituted indoles as MCL-1 protein inhibitors and their preparation. PCT Int. Appl. WO20080131000 A2, 2008.
32. Salituro, F. G.; Harrison, B. L.; Baron, B. M.; Nyce, P. L.; Stewart, K. T.; McDonald, I. A. 3-(2-Carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-d-aspartate receptor complex J. Med. Chem. 1990, 33, 2944-2946
33. Petros, A. M.; Swann, S. L.; Song, D.; Swinger, K.; Park, C.; Zhang, H.; Wendt, M. D.; Kunzer, A. R.; Souers, A. J.; Sun, C. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein Bioorg. Med. Chem. Lett. 2014, 24, 1484-1488
34. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure of BCL-XL-BAK peptide complex: recognition between regulators of apoptosis Science 1997, 275, 983-986
35. Hajduk, P. J.; Mendoza, R.; Petros, A. M.; Huth, J. R.; Bures, M.; Fesik, S. W.; Martin, Y. C. Ligand binding to domain-3 of human serum albumin: a chemometric analysis J. Comput.-Aided Mol. Des. 2003, 17, 93-102
36. Wendt, M. D.; Shen, W.; Kunzer, A.; McClellan, W. J.; Bruncko, M.; Oost, T. K.; Ding, H.; Joseph, M. K.; Zhang, H.; Nimmer, P. M.; Ng, S.; Shoemaker, A. R.; Petros, A. M.; Oleksijew, A.; Marsh, K.; Bauch, J.; Oltersdorf, T.; Belli, B. A.; Martineau, D.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo J. Med. Chem. 2006, 49, 1165-1181
37. Tunquist, B. J.; Woessner, R. D.; Walker, D. H. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520 Mol. Cancer Ther. 2010, 9, 2046-2056
38. Leverson, J. D.; Zhang, H.; Chen, J.; Tahir, S. K.; Phillips, D. C.; Xue, J.; Nimmer, P.; Jin, S.; Smith, M.; Xiao, Y.; Kovar, P.; Tanaka, A.; Bruncko, M.; Sheppard, G. S.; Wang, L.; Gierke, S.; Kategaya, L.; Anderson, D. J.; Wong, C.; Eastham-Anderson, J.; Ludlam, M. J. C.; Sampath, D.; Fairbrother, W. J.; Wertz, I.; Rosenberg, S. H.; Tse, C.; Elmore, S. W.; Souers, A. J. Potent and selective small molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) Cell Death Dis. 2015, 6, e1590
39. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios Drug Metab. Dispos. 2007, 35, 660-666
40. Prueksaritanont, T.; Deluna, P.; Gorham, L. M.; Ma, B.; Cohn, D.; Pang, J.; Xu, X.; Leung, K.; Lin, J. H. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism Drug Metab. Dispos. 1998, 26, 520-527
41. Zhang, H.; Nimmer, P.; Rosenberg, S. H.; Ng, S. C.; Joseph, M. Development of a high-throughput fluorescence polarization assay for BCL-XL Anal. Biochem. 2002, 307, 70-75